Ethicon, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1992-01-01

Employees: 10K

Market Cap: -

Website: http://www.ethicon.com

Clinical Trials

The Paediatric EVICEL® Neuro Study

Phase 3

Terminated

Conditions: CSF Leak

Interventions: Other: Sutures Only
Biological: EVICEL® Fibrin Sealant

First Posted Date: 2014-12-05

Last Posted Date: 2023-07-14

Lead Sponsor: Ethicon, Inc.

Target Recruit Count: 40

Registration Number: NCT02309645

Locations: 🇬🇧
Clinical Investigation Site #21, Liverpool, United Kingdom
🇬🇧
Clinical Investigation Site #25, London, United Kingdom
🇬🇧
Clinical Investigation Site #24, Edinburgh, United Kingdom

and more 4 locations

The Paediatric EVICEL® Soft Tissue and Parenchymal Organ Bleeding Study

Phase 3

Completed

Conditions: Soft Tissue Bleeding
Hemorrhage

Interventions: Biological: EVICEL® Fibrin Sealant
Device: SURGICEL® Absorbable Hemostat

First Posted Date: 2014-08-28

Last Posted Date: 2020-08-31

Lead Sponsor: Ethicon, Inc.

Target Recruit Count: 40

Registration Number: NCT02227706

Locations: 🇧🇪
Clinical Investigation Site #31, Brussels, Belgium
🇨🇦
Clinical Investigation Site #42, Hamilton, Ontario, Canada
🇬🇧
Clinical Investigation Site #21, Birmingham, United Kingdom

and more 10 locations

The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study

Phase 3

Completed

Conditions: Hemorrhage
Soft Tissue Bleeding
Hepatic Parenchyma Bleeding

Interventions: Device: SURGICEL®
Biological: EVARREST™ Sealant Matrix

First Posted Date: 2014-08-28

Last Posted Date: 2023-09-08

Lead Sponsor: Ethicon, Inc.

Target Recruit Count: 40

Registration Number: NCT02227992

Locations: 🇬🇧
Clinical Investigation Site #21, Birmingham, United Kingdom
🇬🇧
Clinical Investigation Site #22, Leeds, United Kingdom
🇧🇪
Clinical Investigation Site #32, Brussels, Belgium

and more 7 locations

The Bioseal Vascular Study

Phase 4

Completed

Conditions: Vascular Bleeding
Cardiovascular Bleeding
Hemorrhage

Interventions: Biological: Bioseal Fibrin Sealant
Other: Manual Compression

First Posted Date: 2014-03-24

Last Posted Date: 2018-03-08

Lead Sponsor: Ethicon, Inc.

Target Recruit Count: 252

Registration Number: NCT02094885

Locations: 🇨🇳
Clinical Investigation Site #21, Guangzhou City, Guangdong, China
🇨🇳
Clinical Investigation Site #32, Nanjing, Jiangsu, China
🇨🇳
Clinical Investigation Site #30, Jinan, Shandong, China

and more 6 locations

The Fibrin Pad CV Phase III Study

Phase 3

Completed

Conditions: Cardiovascular Disease

Interventions: Biological: EVARREST™ Fibrin Sealant Patch
Biological: Topical hemostat

First Posted Date: 2014-01-20

Last Posted Date: 2017-08-15

Lead Sponsor: Ethicon, Inc.

Target Recruit Count: 156

Registration Number: NCT02040428

Locations: 🇺🇸
Clinical Investigation Site #14, Indianapolis, Indiana, United States
🇺🇸
Clinical Investigation Site #16, Baltimore, Maryland, United States
🇦🇺
Clinical Investigation Site #73, Sydney, New South Wales, Australia

and more 21 locations

Phase IV Bioseal Study in Brain Tumor Surgery

Phase 4

Completed

Conditions: Hemostasis
Meningioma Surgery

Interventions: Other: Standard of Care (SoC)
Biological: Bioseal Fibrin Sealant

First Posted Date: 2014-01-14

Last Posted Date: 2018-02-26

Lead Sponsor: Ethicon, Inc.

Target Recruit Count: 256

Registration Number: NCT02034799

Locations: 🇨🇳
Clinical Investigation Site #5, Changsha, Hunan, China
🇨🇳
Clinical Investigation Site #4, Hangzhou, Zhejiang, China
🇨🇳
Clinical Investigation Site #7, Beijing, China

and more 4 locations

The EVARREST® Fibrin Sealant Patch Liver Study

Phase 3

Completed

Conditions: Hemorrhage

Interventions: Biological: EVARREST® Fibrin Sealant Patch
Other: Standard of Care (SoC)

First Posted Date: 2013-11-25

Last Posted Date: 2016-07-11

Lead Sponsor: Ethicon, Inc.

Target Recruit Count: 102

Registration Number: NCT01993888

Locations: 🇺🇸
Clinical Investigation Site #13, Birmingham, Alabama, United States
🇺🇸
Clinical Investigation Site #10, Augusta, Georgia, United States
🇺🇸
Clinical Investigation Site #16, Chicago, Illinois, United States

and more 14 locations

EVARREST™ Fibrin Sealant Patch Post-Market Study

Phase 4

Completed

Conditions: Hemorrhage
Soft Tissue Bleeding

Interventions: Other: Standard of Care
Biological: EVARREST™ Fibrin Sealant Patch

First Posted Date: 2013-07-18

Last Posted Date: 2018-01-17

Lead Sponsor: Ethicon, Inc.

Target Recruit Count: 150

Registration Number: NCT01902459

Locations: 🇺🇸
Clinical Site #10, Saint Louis, Missouri, United States

Occipital Nerve Stimulation in the Treatment of Migraine

Phase 1

Terminated

Conditions: Migraine

Interventions: Device: Stimulation of the Occipital Nerves

First Posted Date: 2013-05-16

Last Posted Date: 2013-07-17

Lead Sponsor: Ethicon, Inc.

Target Recruit Count: 1

Registration Number: NCT01855672

Locations: 🇺🇸
Community Research, Cincinnati, Ohio, United States
🇺🇸
Clinilabs, New York, New York, United States
🇺🇸
ActivMed, Newington, New Hampshire, United States

and more 1 locations

The Fibrin Pad Cardiovascular Study

Phase 2

Completed

Conditions: Cardiovascular Disease

Interventions: Biological: Topical hemostat
Biological: EVARREST™
Other: Standard of Care

First Posted Date: 2012-09-07

Last Posted Date: 2018-06-12

Lead Sponsor: Ethicon, Inc.

Target Recruit Count: 42

Registration Number: NCT01681030

Locations: 🇺🇸
Clinical Investigation Site #1, Paterson, New Jersey, United States
🇺🇸
Clinical Investigation Site #3, New York, New York, United States
🇺🇸
Clinical Investigation Site #5, Indianapolis, Indiana, United States

and more 3 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy